Sandra Van Der Vaart Net Worth

The estimated Net Worth of Der Vaart Sandra D Van is at least $3.46 Million dollars as of 19 August 2024. Ms. Van owns over 2,000 units of Labcorp stock worth over $800,906 and over the last 6 years she sold LH stock worth over $2,656,156. In addition, she makes $0 as Executive Vice President, Chief Legal Officer, and Chief Compliance Officer and Secretary at Labcorp.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Vaart LH stock SEC Form 4 insiders trading

Sandra has made over 28 trades of the Labcorp stock since 2019, according to the Form 4 filled with the SEC. Most recently she sold 2,000 units of LH stock worth $454,100 on 19 August 2024.

The largest trade she's ever made was exercising 6,158 units of Labcorp stock on 27 March 2024 worth over $1,344,230. On average, Sandra trades about 877 units every 52 days since 2019. As of 19 August 2024 she still owns at least 3,669 units of Labcorp stock.

You can see the complete history of Ms. Van stock trades at the bottom of the page.

Sandra Van Der Vaart biography

Sandra D. Van Der Vaart serves as Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary of the Company. From February 2019 until then, Ms. Van der Vaart served as Senior Vice President, Global General Counsel and Chief Compliance Officer and Corporate Secretary. Prior to that she served as LabCorp’s Senior Vice President, Deputy Chief Legal Officer from September 2015 until February 2019 and Senior Vice President, General Counsel and Assistant Secretary from January 2009 until September 2015. Prior to serving in these roles, Ms. van der Vaart served in various other roles within the legal department at the Company beginning in January 2001.

How old is Sandra Vaart?

Sandra Vaart is 60, she's been the Executive Vice President, Chief Legal Officer, and Chief Compliance Officer and Secretary of Labcorp since 2020. There are 6 older and 17 younger executives at Labcorp. The oldest executive at Labcorp Holdings Inc. is Jean-Luc Belingard, 71, who is the Independent Director.

What's Sandra Vaart's mailing address?

Der's mailing address filed with the SEC is 531, South Spring Street, Burlington, Alamance County, North Carolina, 27215, United States.

Insiders trading at Labcorp

Over the last 19 years, insiders at Labcorp have traded over $236,972,149 worth of Labcorp stock and bought 10,666 units worth $1,520,331 . The most active insiders traders include Mahon Thomas P Mac, Garheng Kong, and David P King. On average, Labcorp executives and independent directors trade stock every 11 days with the average trade being worth of $2,652,442. The most recent stock trade was executed by Der Vaart Sandra D Van on 19 August 2024, trading 2,000 units of LH stock currently worth $454,100.

What does Labcorp do?

recognized for our innovation, quality, and customer convenience, labcorp delivers timely, accurate results for improved patient care. with scientific expertise in esoteric testing, genomics, and clinical and anatomic pathology, labcorp performs more than one million tests on approximately 400,000 samples each day. labcorp is a pioneer in applying advances in medicine and science to laboratory testing, with more than 35 years of experience in serving physicians and their patients. labcorp operates a sophisticated laboratory network, with corporate headquarters in burlington, nc, and more than 34,000 employees worldwide. our more than 220,000 clients include physician offices, hospitals, managed care organizations, and biotechnology and pharmaceutical companies. laboratory corporation of america holdings is listed on the new york stock exchange (nyse) under ticker symbol lh.

Complete history of Ms. Van stock trades at Labcorp

Labcorp executives and stock owners

Labcorp executives and other stock owners filed with the SEC include:

• Glenn Eisenberg,
  Chief Financial Officer, Executive Vice President
• Adam Schechter,
  President, Chief Executive Officer, Director
• Adam H. Schechter,
  Pres, CEO & Chairman
• Brian Caveney,
  Executive Vice President, President, Diagnostics and Chief Medical Officer
• Lance Berberian,
  Executive Vice President, Chief Technology Officer, Chief Information Officer
• Mark Schroeder,
  Executive Vice President, President of Diagnostics Laboratory Operations and Global Supply Chain
• Glenn A. Eisenberg,
  CFO & Exec. VP
• Mark S. Schroeder,
  Exec. VP and Pres of Diagnostics Laboratory Operations & Global Supply Chain
• Dr. Paul R. Kirchgraber M.D.,
  Exec. VP & CEO of Covance Drug Devel.
• Dr. Brian J. Caveney M.P.H., M.D., J.D., MPH,
  Exec. VP, Pres of Diagnostics & Chief Medical Officer
• Peter Neupert,
  Lead Independent Director
• Kerrii Anderson,
  Independent Director
• Garheng Kong,
  Independent Director
• Robert Williams,
  Independent Director
• Richelle Parham,
  Independent Director
• D. Gary Gilliland,
  Independent Director
• Jean-Luc Belingard,
  Independent Director
• Jeffrey Davis,
  Independent Director
• Clarissa Willett,
  Vice President, Investor Relations
• Peter Wilkinson,
  Senior Vice President, Chief Accounting Officer
• Paul Kirchgraber,
  Executive Vice President and Chief Executive Officer - Covance Drug Development
• Sandra Van Der Vaart,
  Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary
• Amy Summy,
  Executive Vice President, Chief Marketing Officer
• Judith Seltz,
  Chief Human Resource Officer, Executive Vice President
• Chas Cook,
  VP of Investor Relations
• Dr. Marcia T. Eisenberg Ph.D.,
  Chief Scientific Officer & Sr. VP
• Lance V. Berberian,
  Exec. VP and Chief Information & Technology Officer
• Peter J. Wilkinson,
  Sr. VP & Chief Accounting Officer
• Dr. Michelle Abelson Ph.D.,
  Laboratory Director of Operations
• Anita Z Graham,
  EVP, CHRO
• R Sanders Williams,
  Director
• Edward T Dodson,
  Principal Accounting Officer
• Lisa J Uthgenannt,
  Chief Human Resources Officer
• David P King,
  Director
• M. Huff Gary,
  CEO, LabCorp Diagnostics
• John D Ratliff,
  CEO, Covance Drug Development
• F Samuel Iii Eberts,
  Chief Legal Officer, Secretary
• Robert E Jr Mittelstaedt,
  Director
• Kathryn E Wengel,
  Director
• Thomas Pike,
  Pres & CEO Clinical Business
• Arthur H Rubenstein,
  Director
• M Keith Weikel,
  Director
• William B Hayes,
  Sr. Vice President
• Wendy E Lane,
  Director
• Lidia Fonseca,
  Chief Information Officer
• Bradford T Smith,
  EVP, Chf Legal Offcr,Secretary
• Don M Hardison,
  EVP, COO
• Mahon Thomas P Mac,
  CEO and Chairman of the Board
• N Anthony Coles,
  Director
• William Haas,
  EVP, Sales & Marketing
• Andrew J Conrad,
  EVP, Chief Scientific Officer
• Goldman Myla Lai,
  EVP & Chief Medical Officer
• Benjamin R Miller,
  EVP, Oncology Products & Serv
• Andrew G Wallace,
  Director
• Allen W Troub,
  EVP, Western Operations
• Woodrow L Cook,
  EVP, Eastern Operations
• Richard L Novak,
  EVP & Strategic Planning
• Deborah L Keller,
  CEO, Covance Drug Development
• James T. Jr. Boyle,
  Senior Vice President
• Joseph L Herring,
  CEO of Covance Drug Division
• Mark E Brecher,
  Chief Medical Officer
• Kirsten Marie Kliphouse,
  Director
• Paul Rothman,
  Director
• Jonathan P. Di Vincenzo,
  EVP, Pres, Central Labs & Intl
• Megan D. Bailey,
  EVP, Chief Strategy Officer